Endometriosis is a painful disorder in which tissue similar to the lining inside the uterus (called “the endometrium”) grows outside of the uterus, where it induces a chronic inflammatory reaction that may result in scar tissue. The symptoms of endometriosis include significant pain that accompanies periods, ovulation, and sexual intercourse as well as heavy menstrual bleeding, chronic pelvic pain, fatigue and infertility. Endometriosis can also affect general physical, mental, and social well being.
An estimated 2.5 million women in the US have been diagnosed and are being treated for the painful and debilitating symptoms of endometriosis. However, available treatments fail to control the pain associated with the disease over the long term. The only approved class of treatments for endometriosis—gonadotropin-releasing hormone (GnRH) agonists—work by excessively suppressing estrogen/estradiol production, which may lead to bone mineral density loss or other adverse effects.
ObsEva is currently advancing OBE2109, a novel, oral gonadotropin-releasing hormone (GnRH) receptor antagonist that potentially provides effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with currently approved treatments.
For a list of all ObsEva clinical trials in the area of endometriosis, click here.
